SANES

10.708

+0.19%↑

BBVA

19.545

-0.79%↓

BNP

93.59

-0.52%↓

CABK

11.515

-0.6%↓

INGA

26.21

-1.3%↓

SANES

10.708

+0.19%↑

BBVA

19.545

-0.79%↓

BNP

93.59

-0.52%↓

CABK

11.515

-0.6%↓

INGA

26.21

-1.3%↓

SANES

10.708

+0.19%↑

BBVA

19.545

-0.79%↓

BNP

93.59

-0.52%↓

CABK

11.515

-0.6%↓

INGA

26.21

-1.3%↓

SANES

10.708

+0.19%↑

BBVA

19.545

-0.79%↓

BNP

93.59

-0.52%↓

CABK

11.515

-0.6%↓

INGA

26.21

-1.3%↓

SANES

10.708

+0.19%↑

BBVA

19.545

-0.79%↓

BNP

93.59

-0.52%↓

CABK

11.515

-0.6%↓

INGA

26.21

-1.3%↓

Home・Aktien・Ipsen SA.

Ipsen SA.

Open

BrancheFinanzen

155.6 2.64

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

151.4

Max

154.9

Schlüsselkennzahlen
By Trading Economics
Einkommen	-225M 110M
Verkäufe	36M 1.9B
KGV Branchendurchschnitt	28.534 41.721
Dividendenrendite	0.89
Gewinnspanne	5.899
Angestellte	5,535
EBITDA	-171M 466M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	-5.58% downside

Dividenden
By Dow Jones
Dividendenrendite Branchendurchschnitt	0.89% 4.65%
Nächstes Ergebnis	30. Juli 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	1.1B 13B
Vorheriger Eröffnungskurs	152.96
Vorheriger Schlusskurs	155.6

Nachrichtenstimmung

By Acuity

42%

58%

120 / 439 Ranking in Finance

Ipsen SA. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Ipsen SA. Prognose

Kursziel

By TipRanks

-5.58% Nachteil

12-Monats-Prognose

Durchschnitt 143.8 EUR -5.58%

Hoch 170 EUR

Tief 117 EUR

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Ipsen SA. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Ipsen SA. – Dist abgegeben haben.

Stimmung

By Acuity

120 / 439 Ranking in Finanzen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.